Hanover brings market access to life.
We use our unique blend of access, policy, and communications expertise to build and implement compelling value and engagement strategies.
Working with pharmaceuticals, health-tech, and biotech in-market and internationally, we support clients to understand and shape the pre-launch environment, prepare for HTA and value-based agreements, and translate value data into advocacy and communications programmes that connect with customers.
In short, we help companies bring therapies and technologies to patients.
This is an era of incredible science and new breakthrough treatments. Policy makers, payers, value assessors and health system leaders want timely access to these innovative treatments, whilst ensuring best value and the sustainability of their healthcare systems.
With payer budget constraints deepening, and the use of value frameworks spreading to new markets, there is more pressure than ever on companies to demonstrate the value of their products.
Hanover’s team includes people from government, pharma and biotech policy and access teams, from HTA (including NICE’s former HST programme lead) plus an advisor network of former senior health system and policy leaders.
Our market access work integrates with government and public affairs, health policy, and product and corporate communications to create a unique offer. We can help you to cut through and bring your product’s true value to life.
Through its owned offices, AVENIR GLOBAL partners, and network of hand-picked agencies in key geographies, Hanover can reach into the 20 top markets worldwide, and deliver regional and global insights, strategies, and execution. We can also support you internally to connect different functions in a unified commercial approach.
For more information, please contact: Andrew Harrison, Group Managing Director, Health.